Eridani Pharmaceuticals, Inc
Our lead asset, EP-837, is a novel oral TSHR agonist for patient friendly, cost-effective, diagnosis and treatment of differentiated thyroid cancer
- Stage Product In Development
- Industry Biotechnology
- Location Doylestown, PA, US
- Currency USD
- Founded January 2016
- Employees 5
- Incorporation Type C-corp
- Website http://lazaruspharma.com HOLDING COMPANY
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.